CMP-001
Jump to navigation
Jump to search
Indications
- treatment of pembrolizumab-resistant cutaneous melonoma
Dosage
- direct intratumoral injection
* requires accessible lesion such as a skin lesion or a palpable subcutaneous lesion, or a lymph node
Mechanism of action
- synthetic immunostimulatory DNA molecule (CpG-A) encased in a nonreplicating virus-like particle that protects the DNA from degradation
- stimulates TLR9 activity
- activation of tumor-associated dendritic cells
- induction of an IFN & antitumor T-cell activation
More general terms
References
- ↑ Bankhead C Drug May Reverse Anti-PD-1 Resistance in Melanoma. Responses in 22% of resistant patients with TLR9 agonist. MedPage Today. April 19, 2018 https://www.medpagetoday.com/meetingcoverage/aacr/72435
Milhem M, et al Intratumoral toll-like receptor 9 (TLR9) agonist, CMP-001, in combination with pembrolizumab can reverse resistance to PD-1 inhibition in a phase Ib trial in subjects with advanced melanoma. American Association for Cancer Research (AACR 2018) Abstract CT144